U.S. patent application number 14/812515 was filed with the patent office on 2016-06-02 for stable formulations for parenteral injection of small molecule drugs.
The applicant listed for this patent is Xeris Pharmaceuticals, Inc.. Invention is credited to Steven J. PRESTRELSKI, Nancy SCOTT.
Application Number | 20160151385 14/812515 |
Document ID | / |
Family ID | 49778742 |
Filed Date | 2016-06-02 |
United States Patent
Application |
20160151385 |
Kind Code |
A1 |
PRESTRELSKI; Steven J. ; et
al. |
June 2, 2016 |
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE
DRUGS
Abstract
Disclosed is a stable liquid formulation for parenteral
injection comprising a biocompatible non-aqueous solvent and a
small molecule drug, or a salt thereof, solubilized within the
non-aqueous solvent, wherein the liquid formulation comprises less
than 10% by weight residual water, and wherein the volume of the
liquid formulation to be parenterally injected is from 0.1 .mu.l to
3 ml.
Inventors: |
PRESTRELSKI; Steven J.; (San
Diego, CA) ; SCOTT; Nancy; (Austin, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Xeris Pharmaceuticals, Inc. |
Austin |
TX |
US |
|
|
Family ID: |
49778742 |
Appl. No.: |
14/812515 |
Filed: |
July 29, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13829937 |
Mar 14, 2013 |
9125805 |
|
|
14812515 |
|
|
|
|
61665021 |
Jun 27, 2012 |
|
|
|
Current U.S.
Class: |
514/221 |
Current CPC
Class: |
A61K 31/4196 20130101;
A61K 31/352 20130101; A61K 47/14 20130101; A61K 9/08 20130101; A61K
31/7036 20130101; A61K 9/0019 20130101; A61K 31/167 20130101; A61K
31/5513 20130101; A61P 25/22 20180101; A61K 47/22 20130101; A61K
31/675 20130101; A61K 47/20 20130101; A61K 47/10 20130101; A61K
31/4045 20130101; A61K 31/55 20130101; A61K 31/496 20130101; A61K
31/137 20130101; A61P 25/06 20180101; A61P 25/08 20180101 |
International
Class: |
A61K 31/5513 20060101
A61K031/5513; A61K 9/08 20060101 A61K009/08; A61K 47/22 20060101
A61K047/22; A61K 9/00 20060101 A61K009/00; A61K 47/20 20060101
A61K047/20 |
Claims
1-20. (canceled)
21. A stable liquid formulation for parenteral injection
comprising: (a) a biocompatible non-aqueous aprotic solvent,
wherein the liquid formulation comprises the aprotic solvent, and
wherein the aprotic solvent is dimethylsulfoxide (DMSO),
dimethylformamide (DMF), ethyl acetate, n-methyl pyrrolidone (NMP),
dimethyl acetamide (DMA), propylene carbonate, or mixtures thereof;
and (b) a small molecule drug, or a salt thereof, solubilized
within the non-aqueous solvent, wherein the small molecule drug is
a benzodiazepine, and wherein the benzodiazepine is present in the
liquid formulation in an amount up to its solubility limit in the
formulation, wherein the liquid formulation comprises less than 10%
by weight residual water, and wherein the volume of the liquid
formulation to be parenterally injected is 3 ml or less.
22. The stable liquid formulation of claim 21, further comprised
within a device for dispensing the liquid formulation.
23. The stable liquid formulation of claim 22, wherein the device
is a syringe, a pen injection device, an auto-injector device, an
external or implantable pump, or a perfusion bag.
24. The stable liquid formulation of claim 21, wherein the aprotic
solvent is DMSO, NMP, or a mixture thereof.
25. The stable liquid formulation of claim 21, wherein the small
molecule drug is diazepam.
26. The stable liquid formulation of claim 25, wherein the liquid
formulation comprises 50 mg/ml to 300 mg/ml of diazepam.
27. The stable liquid formulation of claim 26, wherein the solvent
is DSMO, NMP, or a mixture thereof.
28. The stable liquid formulation of claim 21, wherein the liquid
formulation comprises less than 5% by weight residual water.
29. The stable liquid formulation of claim 21, wherein the liquid
formulation includes from 0.5 mg/mL to 750 mg/ml of the small
molecule drug.
30. The stable liquid formulation of claim 21, wherein the volume
of the liquid formulation to be parenterally injected is from 0.1
.mu.l to 1 .mu.l.
31. The stable liquid formulation of claim 21, wherein the volume
of the liquid formulation to be parenterally injected is from 1
.mu.l to 10 .mu.l.
32. The stable liquid formulation of claim 21, wherein the volume
of the liquid formulation to be parenterally injected is from 10
.mu.l to 1 ml.
33. The stable liquid formulation of claim 21, wherein the volume
of the liquid formulation to be parenterally injected is from 1 ml
to 3 ml.
34. A method of administering the stable liquid formulation of
claim 21 to a subject, the method comprising parenterally injecting
the stable liquid formulation to the subject.
35. The method of claim 34, wherein the stable liquid formulation
is parenterally injected with a syringe, a pen injection device, an
auto-injector device, an external or implantable pump, or a
perfusion bag.
36. The method of claim 34, wherein the stable liquid formulation
is not diluted prior to administration.
37. A method of treating or preventing anxiety, muscle spasms, or
seizures, the method comprising parenterally injecting the liquid
formulation of claim 21 to a subject in need thereof.
38. The method of claim 37, wherein the stable liquid formulation
is parenterally injected with a syringe, a pen injection device, an
auto-injector device, an external or implantable pump, or a
perfusion bag.
39. The method of claim 37, wherein the stable liquid formulation
is not diluted prior to administration.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/829,937 filed Mar. 14, 2013, which claims
the benefit of U.S. Provisional Application No. 61/665,021, filed
Jun. 27, 2012, the entire contents of which are incorporated by
reference.
BACKGROUND OF THE INVENTION
[0002] A. Field of the Invention
[0003] The present invention relates to pharmaceutical formulations
and, more particularly, to pharmaceutical formulations of small
molecule drugs having improved solubility and stability and to
methods of using such pharmaceutical formulations to treat various
diseases, conditions and disorders.
[0004] B. Description of Related Art
[0005] While many small molecule drugs are orally bioavailable,
parenteral injection is also used in situations where the drug has
insufficient oral bioavailability, the patient is unable to accept
drugs orally, or there is a need for more rapid onset of drug
action. For example, administration of benzodiazepines for
emergency treatment of epileptic seizures, catecholamines for
allergic reactions and "triptans" for the treatment of migraine
headaches represent situations where oral administration is not as
efficient or advisable and thus, the drugs must be administered via
a non-oral route, often parenteral administration.
[0006] Standard practice for preparing formulations containing
small molecule drugs has been to develop aqueous solutions for
parenteral injection. A primary reason for this is that the
majority of the human body is made up of water, including blood
plasma, which is an aqueous environment. Therefore, there is a
natural tendency to administer a drug formulation that is
compatible with the environment that the drug is intended to reach.
Several small molecule drugs, however, have limited solubility and
poor stability in such aqueous environments. This has been solved,
at least in part, by the use of co-solvents and stabilizers to more
efficiently solubilize and stabilize the small molecule drug in a
formulation.
[0007] An example of some of the difficulties associated with
parenteral injection of small molecule drugs can be seen with
diazepam. This drug, which is used for emergency treatment of
epileptic seizures, has been hampered by its poor aqueous
solubility. Thus, the currently available emergency treatment
consists of a rectal gel. An attempt has also been made to develop
a large-volume (up to 3 ml) intramuscular injection based on an
aqueous formulation with co-solvents (larger volumes are needed due
to lower solubility of diazepam). However, the development of this
drug has been limited by the difficulty in delivering a deep, large
volume intramuscular injection to a convulsing patient, as well as
the pain associated with such a large dosage volume.
[0008] Further, due to the stability issues of small molecule drugs
in aqueous environments, current products are oftentimes sold as
lyophilized powders that require reconstitution in an aqueous
carrier prior to injection. This allows for longer shelf-life of
the drug active. Some products are even sold as liquids that
require further dilution prior to injection with sterile water,
phosphate buffer solution, or isotonic saline.
SUMMARY OF THE INVENTION
[0009] The present invention provides a solution to the current
problems facing the use of small molecule drugs in therapeutic
applications. In particular, the solution is premised on
solubilizing and stabilizing a small molecule drug in a non-aqueous
environment and then directly injecting the solubilized drug into a
patient via parenteral administration. The formulation can be in
liquid form. Once the formulation is prepared, it can be stored for
an extended period of time (even in an injection device) and
directly injected into a subject (e.g., human) without the
reconstitution or dilution steps seen in current products. Indeed,
this solution goes against the prevailing industry standard. In
this regard, the inventors' solution has resulted in a more stable
environment for the drug and a more efficient and effective way to
actually provide life-saving drugs to those in need of treatment.
Importantly, the inventors' discovery is widely applicable for the
delivery of numerous small molecule drugs that, like diazepam, have
poor or limited stability and solubility in an aqueous
environment.
[0010] In one aspect of the present invention there is disclosed a
stable liquid formulation for parenteral injection comprising a
small molecule drug, or a salt thereof and a biocompatible
non-aqueous solvent, wherein the small molecule drug is solubilized
within the non-aqueous solvent. One of the unique aspects of the
present invention is that it can be used for a wide variety of
small molecule drugs, including those that currently being
administered via parenteral injection. Some examples include
benzodiazepines, catecholamines, and triptans. In one particular
aspect, the compound is a benzodiazepine such as diazepam. The
solubility of diazepam, by way of example, can be greater than what
is typically seen with current products (e.g., the Examples show
that diazepam solubility in DMSO can approach levels of 500 mM,
which would allow for a wide range of dosaging options, such as for
instance, reduced volumes of dosages--for instance, a diazepam
formulation in DMSO can have 100 mM to 500 mM, 150 mM to 400 mM,
175 mM to 350 mM, or 200 mM to 300 mM of the drug, wherein each
concentration provides for a substantially smaller volume to
deliver the same quantity of drug compared to water-based
preparations of diazepam. The Examples also show that the
solubility of diazepam in NMP exceeded 700 mM, which allows for
even smaller dosage volumes as needed). Other non-limiting small
molecule drugs that can be used in the context of the present
invention include epinephrine, sumatriptan, novantrone,
chemotherapy small molecules (e.g., mitoxantrone), corticosteroid
small molecules (e.g., methylprednisolone), immunosuppressive small
molecules (e.g., azathioprine, cladribine, cyclophosphamide,
methotrexate), anti-inflammatory small molecules (e.g., salicylic
acid, acetylsalicylic acid, diflunisal, choline magnesium
trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic
acid, meclofenamic acid, triflumic acid, diclofenac, fenclofenac,
alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen,
naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic
acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac,
indomethacin, sulindac, phenylbutazone, oxyphenbutazone,
azapropazone, feprazone, piroxicam, isoxicam), small molecules used
to treat neurological disorders (e.g., cimetidine, ranitidine,
famotidine, nizatidine, tacrine, donepizil, metrifonate,
rivastigmine, selegilene, imipramine, fluoxetine, olanzapine,
sertindole, risperidone, valproate semisodium, gabapentin,
carbamazepine, topiramate, phenytoin), and small molecules used to
treat cancer (e.g., vincristine, vinblastin, paclitaxel, docetaxel,
cisplatin, irinotecan, topotecan, gemcitabine, temozolomide,
imatinib, bortezomib), statins (e.g., atorvastatin, amlodipine,
rosuvastatin, sitagliptin, simvastatin, fluvastatin, pitavastatin,
lovastatin, pravastatin, simvastatin), and other taxane
derivatives. In particular embodiments, the small molecules that
can be used include those that treat tuberculosis (e.g.,
rifampicin), small molecule anti-fungal agents (e.g., fluconazole),
small molecule anti-anxiety agents and small molecule
anti-convulsant agents (e.g. lorazepam), small molecule
anti-cholinergic agents (e.g., atropine), small molecule f3-agonist
drugs (e.g., albuterol sulfate), small molecule mast cell
stabilizers and small molecule agents used to treat allergies (e.g.
cromolyn sodium), small molecule anesthetic agents and small
molecule anti-arrhythmic agents (e.g., lidocaine), small molecule
antibiotic agents (e.g. tobramycin, ciprofloxacin), small molecule
anti-migraine agents (e.g., sumatriptan), and small molecule
anti-histamine drugs (e.g., diphenhydramine). Further, the amount
of the small molecule drugs in the dosage formulations can be
varied depending on current acceptable amounts, subject/patient
needs, and the like. With respect to the biocompatible non-aqueous
solvent, examples include aprotic polar solvents, alkyl or aryl
benzoate solvents, lipid solvents, protic solvents, or a mixture
thereof. Non-limiting examples of aprotic solvents include
dimethylsulfoxide (DMSO), dimethylformamide (DMF), ethyl acetate,
n-methyl pyrrolidone (NMP), dimethyl acetamide (DMA), propylene
carbonate, or mixtures thereof. In some instances, however, the
formulations of the present invention do not have to include the
aforementioned solvents (i.e., others can be used). In one
instance, for example, the formulations do not include non-aqueous
aprotic polar solvents and/or do not include non-aqueous protic
solvents (e.g., polyethylene glycol (PEG), propylene glycol (PG),
polyvinylpyrrolidone (PVP), methoxypropylene glycol (MPEG),
glycerol, glycofurol, and mixtures thereof). As noted above, the
increased solubility of the small molecule drugs can result in
small dosage volumes (and, in turn, small storage devices and
containers), which provides for an easier and less painful
administration parenterally. Non-limiting examples of aryl or alkyl
benzoate solvents include methyl benzoate, ethyl benzoate, propyl
benzoate, C12-C15 alkyl benzoates, in which R is a C12-15 alkyl
group, C16-17 alkyl benzoate, in which R is a C16-17 fatty alcohol
group, and benzyl benzoate. A non-limiting example of a lipid is
triacetin, which is the triester of glycerol and acetic acid.
Non-limiting examples of protic solvents include polyethylene
glycol (PEG), propylene glycol (PG), polyvinylpyrrolidone (PVP),
methoxypropylene glycol (MPEG), glycerol, glycofurol, or mixtures
thereof. In certain aspects, the formulation does not include a
co-solvent, while in other aspects it can include a co-solvent. In
one instance, the formulation can include a single/only one
biocompatible non-aqueous solvent (i.e., in neat or pure form). In
other aspects, the formulation includes a mixture of two, three,
four, or more biocompatible non-aqueous solvents. In still
additional aspects, the formulation can exclude co-solvents, salts,
and other ingredients that can help with or increase the solubility
of the small molecule drug in the non-aqueous solvent. For
instance, the formulation can consist of or consist essentially of
a small molecule drug and a non-aqueous solvent (or mixture of
non-aqueous solvents) and still be directly injected through
parenteral administration to a subject (with consist essentially of
meaning in the context of this sentence exclusion of other
ingredients that could increase the solubility of the drug within
the non-aqueous solvent (or mixture of non-aqueous solvents--e.g.,
a preservative can be included to further preserve the injectible
formulation). Further, the formulation of the present invention can
be non-aqueous or substantially non-aqueous (e.g., less than 10%,
9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of water by weight
or volume). In some instances, the small molecule drug has
previously been dried in the presence of a buffer prior to being
solubilized in the non-aqueous solvent. As explained below, this
can add to the stability of the small molecule drug. In some
instances, the dried small molecule drug has a pH memory that is
about equal to the pH of the small molecule drug in the presence of
the aqueous buffer such that the pH of the small molecule drug that
is solubilized in the biocompatible non-aqueous solvent is about
equal to the pH of the small molecule drug in the presence of the
buffer. The memory pH can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or
more or can be a range of 1 to 3, 2 to 4, 3 to 5, 4 to 6, 5 to 7, 6
to 8, 7 to 9, 8 to 10 or 9 to 11. In certain aspects, the buffer is
a non-volatile buffer (non-limiting examples of which include
glycine buffers, citrate buffers, or phosphate buffers, or a
mixture thereof). In other instances, the buffer can be a volatile
buffer. Further, the water content of the small molecule drug can
be less than 5%, 4%, 3%, 2%, 1%, 0.5% or less w/w. In certain
aspects, the formulation includes from 0.5 mg/mL to about 300
mg/mL, 10 mg/mL to 50 mg/mL, 20 mg/mL to 50 mg/mL, 5 mg/mL to 15
mg/mL, or 0.5 mg/mL to 2 mg/mL of the small molecule drug. In some
instances, the amount of the small molecule drug can be as high as
400, 500, 600, 700, 800, 900, 1000, 2000, or 3000 mg/mL or more.
One of the unique aspects of the present formulation is that the
formulation can have a high content of the drug, yet the dosage
amount of the formulation can be relatively low (e.g., 0.1.mu., 1
.mu.l, 10 .mu.l, 20, .mu.l, 50 .mu.l, 75 .mu.l, 100 .mu.l, 200
.mu.l, 300 .mu.l, 400 .mu.l, 500 .mu.l, 600 .mu.l, 700 .mu.l, 800
.mu.l, 900 .mu.l, 1 ml, 2 ml, or 3 ml, or more as needed (e.g., 4,
5, 6, 7, 8, 9, 10 ml or more). In certain instances, the volume of
the liquid formulation to be parenterally injected is 3 ml or less
(e.g., 3, 2.5, 2, 1.5, 1, 0.5, 0.1 ml or less) or is from 0.1 .mu.l
to 3 ml or from 0.1 .mu.l to 1 .mu.l or from 1 .mu.l to 10 .mu.l or
from 10 .mu.l to 1 ml or from 0.1 .mu.l to 2.5 ml or from 0.1 .mu.l
to 2 ml or from 0.1 .mu.l to 1.5 ml or from 0.1 .mu.l to 1 ml or
from 0.1 .mu.l to 0.5 ml or from 0.1 .mu.l to 0.1 ml. Another
unique aspect of the present formulation is that it can be
contained in a container or device, be stored, and be immediately
ready for parenteral injection on an as needed basis without having
to reconstitute or dilute the formulation. The device can be a
syringe, a pen injection device, an auto-injector device, a device
that can pump or administer the formulation (e.g., automatic or
non-automatic external pumps, implantable pumps, etc.) or a
perfusion bag. Also contemplated for use in the formulations are
additional ingredients/pharmaceutical excipients, non-limiting
example of which include: antioxidants (examples include ascorbic
acid, cysteine, methionine, monothioglycerol, sodium thiosulfate,
sulfites, BHT, BHA, ascorbyl palmitate, propyl gallate, or vitamin
E); chelating agents (examples include EDTA, EGTA, tartaric acid,
glycerin, or citric acid); or preservatives (examples include alkyl
alcohols, benzyl alcohol, a methyl paraben, or a propyl paraben or
mixtures thereof). The formulation can be in liquid form,
semi-solid form, or gel form. As discussed below, the formulation
can have a desired viscosity range (in one non-limiting example,
such a range could be between 0.5 to 15 cps). The formulation can
be such that at least 65% of the small molecule drug within the
formulation remains chemically and physically stable when the
formulation is stored at room temperature for two months or at
least 80% of the therapeutic agent within the formulation remains
chemically and physically stable when the formulation is stored at
room temperature for two months.
[0011] In one particular aspect of the present invention, there is
disclosed a stable liquid formulation for parenteral injection
comprising diazepam, or a salt thereof that has a water content of
less than 1% w/w and a biocompatible non-aqueous solvent, wherein
the diazepam is solubilized within the non-aqueous solvent, wherein
the water content of the formulation is less than 5% w/v, wherein
the volume of the formulation to be parenterally injected is
between 50 .mu.l to 1000 .mu.l or any range therein (e.g., 75
.mu.l, 100 .mu.l, 150 .mu.l, 200 .mu.l, 300 .mu.l, 400 .mu.l, 500
.mu.l, 600 .mu.l, 700 .mu.l, 800 .mu.l, 900 .mu.l, etc.). As
explained above, such a formulation can be comprised in a container
selected from the group con a sealed syringe, a sealed pen
injection device, a sealed auto-injector device, or a pump. Also as
explained above, the diazepam can be been dried in the presence of
a buffer prior to being solubilized in the non-aqueous solvent.
This can provide the dried diazepam with a pH memory that is about
equal to the pH of diazepam in the presence of the aqueous buffer
such that the pH of the diazepam that is solubilized in the
biocompatible non-aqueous solvent is about equal to the pH of the
diazepam in the presence of the aqueous buffer (e.g., the
aforementioned non-volatile buffers such as glycine buffers,
citrate buffers, or phosphate buffers, or a mixture thereof).
[0012] Also disclosed is a method of administering the formulations
of the present invention by parenteral administration of the
formulation to a subject in need thereof. The administration can be
performed without having to reconstitute and/or dilute the
formulation. Further, the administration can be performed with a
syringe, a pen injection device, an auto-injector device, a pump,
or a perfusion bag. Also, the formulation can be stored in said
syringe, pen injection device, auto-injector device, pump, or
perfusion bag, which can then be immediately used (again without
having to reconstitute and/or dilute the formulation). Further, and
as noted above, the amount of the formulation being administered
can range from 1 .mu.l, 10 .mu.l, 20, .mu.l, 50 .mu.l, 75 .mu.l,
100 .mu.l, 200 .mu.l, 300 .mu.l, 400 .mu.l, 500 .mu.l, 600 .mu.l,
700 .mu.l, 800 .mu.l, 900 .mu.l, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6
ml, 7 ml, 8 ml, 9 ml, or 10 ml, or more as needed. In certain
aspects, the formulations are such that the small molecule drug
remains stable and solubilized (i.e., no coalescence or
crystallization of the small molecule drug) and when stored at room
temperature (approximately 20-25.degree. C.) for at least 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
[0013] In a further aspect of the present invention there is
disclosed a method for treating or preventing a condition, disease,
disorder, etc. comprising administering to a subject in need
thereof any one of the formulations of the present invention in an
amount effective to treat or prevent the condition, disease,
disorder, etc. For instance, and with respect to the aforementioned
diazepam formulation, such formulations can be used to treat
epileptic seizure, especially severe seizures in an emergency
situation. In this instance, the method can include administering
to the subject in need thereof a soluble and stable diazepam
formulation of the present invention in an amount effective to
treat the seizure. The aforementioned administration techniques can
be used (e.g., parenterally, pre-loaded containers, etc.). In some
aspects, the condition can be anxiety, muscle spasms, or seizures
(e.g., epileptic seizure).
[0014] Also contemplated is a method of the stable formulations of
the present invention. The method can include obtaining a small
molecule drug and adding one or more biocompatible non-aqueous
solvents in an amount to sufficient dissolve the small molecule
drug in the solvent. The method can further include storing the
formulation in a container such as a vial or in a syringe, a pen
injection device, an auto-injector device, a pump, or a perfusion
bag. The process can further include drying the small molecule drug
in the presence of a buffer prior to adding in the non-aqueous
solvent(s). In a broader aspect, the process can be applied to
formulate any small molecule drug that has limited or poor
solubility or stability in an aqueous environment.
[0015] As briefly mentioned above, it is also contemplated that the
viscosity of the formulations can be selected to achieve a desired
result, e.g., depending on the type of composition desired, the
route of administration, and the like. In one instance, the
viscosity of the formulations can be from about 0.5 cps to well
over 1 million cps or any range or integer derivable therein (e.g.,
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100,
200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000,
5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000,
60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000,
600000, 700000, 800000, 900000, 1000000 cps, etc., as measured on a
Brookfield Viscometer using a TC spindle at 2.5 rpm at 25.degree.
C.). In particular aspects, however, a viscosity range between 0.5
cps to about 100 cps or about 0.5 cps to about 15 cps can be
used.
[0016] It is contemplated that any embodiment discussed in this
specification can be implemented with respect to any method or
composition of the invention, and vice versa. Furthermore,
compositions of the invention can be used to achieve methods of the
invention.
[0017] "Aprotic polar solvent" means a polar solvent that does not
contain acidic hydrogen and does not act as a hydrogen bond donor.
Examples of polar aprotic solvents include dimethylsulfoxide
(DMSO), dimethylformamide (DMF), ethyl acetate, n-methyl
pyrrolidone (NMP), dimethylacetamide (DMA) and propylene
carbonate.
[0018] "Alkyl or aryl benzoates" refers to the following
compound:
##STR00001##
where R is an alkyl or aryl group. Examples of alkyl benzoates
include methyl benzoate, ethyl benzoate, propyl benzoate, C12-C15
alkyl benzoates, in which R is a C12-15 alkyl group, and C16-17
alkyl benzoate, in which R is a C16-17 fatty alcohol group. A
non-limiting example of aryl benzoate includes benzyl benzoate.
[0019] "Parenteral injection" refers to the administration of small
molecule drugs via injection under or through one or more layers of
skin or mucus membranes of an animal, such as a human. Standard
parenteral injections are given into the subcutaneous,
intramuscular, or intradermal region of an animal, e.g., a human
patient. These deep locations are targeted because the tissue
expands more easily, relative to shallow dermal sites, to
accommodate the 0.1-3.0 cc (mL) injection volumes required to
deliver most therapeutic agents.
[0020] "Pharmaceutically acceptable carrier" means a
pharmaceutically acceptable solvent, suspending agent or vehicle
for delivering a drug compound of the present invention to a mammal
such as an animal or human.
[0021] "Pharmaceutically acceptable" ingredient, excipient or
component is one that is suitable for use with humans and/or
animals without undue adverse side effects (such as toxicity,
irritation and allergic response) commensurate with a reasonable
benefit/risk ratio.
[0022] "Chemical stability" means that with respect to the small
molecule drug, an acceptable percentage of degradation products
produced by chemical pathways such as oxidation or hydrolysis is
formed. In particular, a formulation is considered chemically
stable if no more than about 20% breakdown products are formed
after one year of storage at the intended storage temperature of
the product (e.g., room temperature); or storage of the product at
30.degree. C./60% relative humidity for one year; or storage of the
product at 40.degree. C./75% relative humidity for one month, and
preferably three months, and more preferably six months.
[0023] "Physical stability" means that with respect to the small
molecule drug, an acceptable percentage of crystals or other
aggregates (e.g., dimers, trimers, etc.) is formed. In particular,
a formulation is considered physically stable if no more that about
15% aggregates are formed after one year of storage at the intended
storage temperature of the product (e.g., room temperature); or
storage of the product at 30.degree. C./60% relative humidity for
one year; or storage of the product at 40.degree. C./75% relative
humidity for one month, and preferably three months, and more
preferably six months.
[0024] "Stable formulation" means that at least about 65%
chemically and physically stable small molecule drug remains after
two months of storage at room temperature. In some aspects, the
formulations retain at least about 80% chemically and physically
stable small molecule drug under these conditions. Even further,
some stable formulations are those which do not exhibit degradation
after sterilizing irradiation (e.g., gamma, beta or electron
beam).
[0025] "Bioavailability" refers to the extent to which the small
molecule drug is absorbed from the formulation by the subject.
[0026] "Systemic" means, with respect to delivery or administration
of a small molecule drug to a subject, that therapeutic agent is
detectable at a biologically significant level in the blood plasma
of the subject.
[0027] "Controlled-release" refers to the release of the small
molecule drug at such a rate that blood (e.g., plasma)
concentrations are maintained within the therapeutic range, but
below toxic concentrations over a period of time of about one hour
or longer, preferably 12 hours or longer.
[0028] "Patient," "subject," or "individual" refers to a mammal
(e.g., human, primate, dog, cat, bovine, ovine, porcine, equine,
mouse, rate, hamster, rabbit, or guinea pig).
[0029] "Inhibiting" or "reducing" or any variation of these terms,
when used in the claims and/or the specification includes any
measurable decrease or complete inhibition to achieve a desired
result.
[0030] "Effective" or "treating" or "preventing" or any variation
of these terms, when used in the claims and/or specification, means
adequate to accomplish a desired, expected, or intended result.
[0031] The term "about" or "approximately" are defined as being
close to as understood by one of ordinary skill in the art, and in
one non-limiting embodiment the terms are defined to be within 10%,
preferably within 5%, more preferably within 1%, and most
preferably within 0.5%. Further, "substantially non-aqueous" refers
to less than 5%, 4%, 3%, 2%, 1%, or less by weight or volume of
water.
[0032] The use of the word "a" or "an" when used in conjunction
with the term "comprising" in the claims and/or the specification
may mean "one," but it is also consistent with the meaning of "one
or more," "at least one," and "one or more than one."
[0033] The words "comprising" (and any form of comprising, such as
"comprise" and "comprises"), "having" (and any form of having, such
as "have" and "has"), "including" (and any form of including, such
as "includes" and "include") or "containing" (and any form of
containing, such as "contains" and "contain") are inclusive or
open-ended and do not exclude additional, unrecited elements or
method steps.
[0034] The compositions and methods for their use can "comprise,"
"consist essentially of," or "consist of" any of the ingredients or
steps disclosed throughout the specification. With respect to the
transitional phase "consisting essentially of," in one non-limiting
aspect, a basic and novel characteristic of the formulations and
methods disclosed in this specification includes the stability and
solubility of the small molecule drugs within said formulations.
Therefore, ingredients that can negatively or positively affect the
stability or solubility of the small molecule drugs within the
formulations would be excluded from said formulations in instances
where a claim uses the transitional phrase "consisting essentially
of"
[0035] Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the detailed
description and the examples, while indicating specific embodiments
of the invention, are given by way of illustration only.
Additionally, it is contemplated that changes and modifications
within the spirit and scope of the invention will become apparent
to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1: Plasma diazepam levels in rats after administration
of 1 mg diazepam as subcutaneous injections of XeriSol.TM. diazepam
in the indicated solvents or as Diastat rectal gel. Curves
represent 5 animals per group except as otherwise noted.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0037] As discussed above, the difficulties associated with
formulating small molecule drugs for parenteral administration are
well-documented. The current solutions to such difficulties are
also well-documented and accepted as standard practice in the
formulations field. Briefly, the problems begin with the desire to
create aqueous formulations for small molecule drugs that would be
well-tolerated and dispersible within the body (and in particular,
the blood stream) despite the fact that most small molecule drugs
have low solubility and stability in aqueous environments. This
typically results in the use of co-solvents and drug stability
agents, which can result in large and/or multiple dosages (e.g.,
upwards of 3 mL) to ensure that a sufficient amount of the drug is
administered. Further, the added steps of reconstitution and/or
dilution prior to injection can be costly and time consuming.
[0038] To address the current issues associated with parenteral
administration of small molecule drugs, the inventors offer a
unique approach that goes against the well-accepted and traditional
formulation standards. In particular, the inventors have discovered
that by solubilizing a small molecule drug in a non-aqueous
environment, the resulting formulation is not only highly
concentrated with the drug (which then leads to a lower dosage
volume of the formulation), it also provides for increased
stability and solubility of said drug. This in-turn leads to a more
stable formulation that enjoys a longer shelf/storage life that can
be directly injected into a subject without the use of a
reconstitution or dilution step. Thus, the formulations of the
present invention can be stored in a device that can immediately be
used for parenteral administration.
[0039] These and other non-limiting aspects of the present
invention are discussed below.
A. Small Molecule Drugs
[0040] "Small molecule drugs" in the context of the present
invention are biologically active compounds (and salts thereof)
that can bring about a desired, beneficial, and/or pharmacological
effect on a subject. These "small molecule drugs" are organic or
inorganic compounds, but they are not polymers (e.g., peptides,
proteins, polypeptides, carbohydrates, and nucleic acids).
Therefore, the small molecule drugs in the context of the present
invention are not polymeric compounds. Typically, the small
molecule drugs have a molecular weight of less than approximately
1000 Daltons. Certain small molecule drugs are "moisture sensitive"
in that they are increasingly unstable in the presence of water.
Also, salts that can be used with the small molecule drugs are
known to those skilled in the art and include salts with inorganic
acids, organic acids, inorganic bases, or organic bases.
[0041] Non-limiting examples of a few classes of small molecule
drugs that can be used in the context of the present invention
include benzodiazepines, catecholemines, and "triptans." As noted
in the examples, one such drug diazepam, has been shown to work
well in the context of the present invention as evidenced by its
increased stability and solubility in a non-aqueous solvent. Other
non-limiting examples include epinenpherine, sumatriptan,
novantrone, chemotherapy small molecules (e.g., mitoxantrone),
corticosteroid small molecules (e.g., methylprednisolone,
beclomethasone dipropionate), immunosuppressive small molecules
(e.g., azathioprine, cladribine, cyclophosphamide monohydrate,
methotrexate), anti-inflammatory small molecules (e.g., salicylic
acid, acetylsalicylic acid, diflunisal, choline magnesium
trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic
acid, meclofenamic acid, triflumic acid, diclofenac, fenclofenac,
alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen,
naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic
acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac,
indomethacin, sulindac, phenylbutazone, oxyphenbutazone,
azapropazone, feprazone, piroxicam, isoxicam), small molecules used
to treat neurological disorders (e.g., cimetidine, ranitidine,
famotidine, nizatidine, tacrine, donepizil, metrifonate,
rivastigmine, selegilene, imipramine, fluoxetine, olanzapine,
sertindole, risperidone, valproate semisodium, gabapentin,
carbamazepine, topiramate, phenytoin), small molecules used to
treat cancer (e.g., vincristine, vinblastin, paclitaxel, docetaxel,
cisplatin, irinotecan, topotecan, gemcitabine, temozolomide,
imatinib, bortezomib), statins (e.g., atorvastatin, amlodipine,
rosuvastatin, sitagliptin, simvastatin, fluvastatin, pitavastatin,
lovastatin, pravastatin, simvastatin), and other taxane
derivatives, small molecules used to treat tuberculosis (e.g.,
rifampicin), small molecule anti-fungal agents (e.g., fluconazole),
small molecule anti-anxiety agents and small molecule
anti-convulsant agents (e.g., lorazepam), small molecule
anti-cholinergic agents (e.g., atropine), small molecule f3-agonist
drugs (e.g., albuterol sulfate), small molecule mast cell
stabilizers and small molecule agents used to treat allergies
(e.g., cromolyn sodium), small molecule anesthetic agents and small
molecule anti-arrhythmic agents (e.g., lidocaine), small molecule
antibiotic agents (e.g., tobramycin, ciprofloxacin), small molecule
anti-migraine agents (e.g., sumatriptan), and small molecule
anti-histamine drugs (e.g., diphenhydramine).
[0042] Each of the aforementioned drugs are well-known and
commercially available from a wide variety of sources. Further, the
amount of the small molecule drugs in the dosage formulations can
be varied depending on current acceptable amounts, subject/patient
needs (e.g., age, health, weight, nature and extend of symptom),
and the like. What is unique in the context of the present
invention is the fact that the dosage volumes can be decreased, and
concentrated liquid preparations of the compounds can be pre-made
and stored, given the increased solubility and stability of the
small molecule drugs within the formulations of the present
invention.
B. Biocompatible Non-Aqueous Solvents
[0043] "Biocompatible non-aqueous solvent" in the context of the
present invention refers to a solvent that is substantially to
completely devoid of water and is capable of solubilizing a small
molecule drug. The solvent is also biocompatible in that it is
suitable for use with human or animals without undue adverse side
effects (such as toxicity, irritation, and allergic response)
commensurate with a reasonable benefit/risk ratio.
[0044] Non-limiting examples of some suitable biocompatible,
non-aqueous solvents include aprotic polar solvents, alkyl or aryl
benzoates, and lipids. Examples of polar aprotic solvents include
dimethylsulfoxide (DMSO), dimethylformamide (DMF), ethyl acetate,
n-methyl pyrrolidone (NMP), dimethylacetamide (DMA), propylene
carbonate, and mixtures thereof. Non-limiting examples of alkyl
benzoates include methyl benzoate, ethyl benzoate, propyl benzoate,
C12-C15 alkyl benzoates, in which R is a C12-15 alkyl group, and
C16-17 alkyl benzoate, in which R is a C16-17 fatty alcohol group.
A non-limiting example of aryl benzoate includes benzyl benzoate. A
non-limiting example of a lipid is triacetin, which is the triester
of glycerol and acetic acid.
[0045] Each of the aforementioned non-aqueous solvents are
well-known and commercially available from a wide variety of
sources.
C. pH Memory
[0046] In addition to the non-aqueous solvent aspect of the present
invention, the inventors also discovered a further processing step
that can be used to further stabilize the small molecule drug
within the formulation. In particular, a small molecule drug can be
mixed with a non-volatile buffer, and then dried to obtain a small
molecule drug powder. Drugs are susceptible to hydrolysis at
certain bonds, so the use of non-volatile buffers in the
formulations of the present invention are believed to beneficially
affect their chemical stability. The result of this process step is
the production of a "pH memory" of the small molecule drug after it
is reconstituted in then non-aqueous solvent.
[0047] In particular, the "pH memory" of small molecule drug is the
resulting charge profile (protonation state) after drying the drug
from a buffered aqueous solution (e.g., from a non-volatile
buffer). The protonation state, and thus the solubility and
stability of the drug, in very low or zero moisture non-aqueous
solvents are affected by the aqueous pH of the drug solution before
drying and the drying conditions employed. Similarly, the stability
of uncharged drugs is impacted by pH in aqueous solutions, and
thus, pH memory in a dried state or in a non-aqueous solvent. When
the drug is dried in a buffer species in which both the acidic and
basic components are non-volatile, the pH memory of the dried drug
will be about equal to the pH of the drug in the non-volatile
buffer. See, e.g., Enzymatic Reactions in Organic Media, Koskinen,
A. M. P., and Klibanov, A.M., eds., Springer (1996). Furthermore,
the pH of the buffered aqueous solution (e.g., non-volatile buffer)
in which the drug is dried can be optimized to yield a pH memory
for the drug that results in optimal drug stability, maximum
solubility, and minimal degradation when the dried drug is
subsequently reconstituted in the non-aqueous solvent (e.g.,
aprotic polar solvent). It should be noted that many non-aqueous
solvents do not have exchangeable protons. Therefore, when a dried
drug is reconstituted into such a solvent, the drug in the
reconstituted formulation will maintain the solubility and
stability characteristics of the optimal pH memory. In particular
embodiments, the drug in the formulation will have a pH memory of
about 2.0 to 3.0 to ensure maximal stability/minimal degradation.
In other embodiments, the drug in the formulation will have a pH
memory of about 3.0 to 5.0 to ensure maximal stability/minimal
degradation. In yet other embodiments, the drug will have a pH
memory of about 4.0 to 6.0 to ensure maximal stability/minimal
degradation. In yet other embodiments, the drug will have a pH
memory of about 6.0 to 11.0 to ensure maximal stability/minimal
degradation.
[0048] The pH memory of a drug can be measured in several ways. In
one method, the pH memory of a drug is measured by reconstituting
the dried drug into un-buffered water and measuring the pH of the
reconstituted drug with a pH indicator such as pH paper or a
calibrated pH electrode. Alternatively, the pH memory of a drug can
be determined for a drug that has been reconstituted in a
non-aqueous solvent by adding at least 20% water to the non-aqueous
solvent and measuring the pH with a pH indicator. See, e.g.,
Baughman and Kreevoy, "Determination of Acidity in 80% Dimethyl
Sulfoxide-20% Water," Journal a/Physical Chemistry, 78(4):421-23
(1974). Measurement of pH in an aprotic polar solvent-water
solution may require a small correction (i.e., no more than 0.2 pH
unit as per Baughman and Kreevoy, supra).
[0049] In view of the above, non-volatile buffers that are useful
in the formulations described herein are those that are helpful in
establishing a pH of maximum stability/minimal degradation as well
as those that are helpful in removing residual water content from
the dried drug powder. Nonvolatile buffers include those buffers
that will not evaporate away in a manner similar to water upon
drying/lyophilization. Suitable nonvolatile buffers include, for
example, glycine buffers, citrate buffers and phosphate buffers. In
one preferred embodiment, the nonvolatile buffer is a glycine
buffer or a citrate buffer.
[0050] In the foregoing process, drying of the drug compound with
the nonvolatile buffer can be carried out using spray-drying
techniques, freeze-drying techniques or lyophilization techniques.
Spray drying techniques are well known to those skilled in the art.
Spray drying includes the steps of atomization of a solution
containing one or more solids (e.g., therapeutic agent) via a
nozzle spinning disk, or other device, followed by evaporation of
the solvent from the droplets. The nature of the powder that
results is the function of several variables including the initial
solute concentration, size distribution of droplets produced and
the rate of solute removal. The particles produced may comprise
aggregates of primary particles which consist of crystals and/or
amorphous solids depending on the rate and conditions of solvent
removal.
[0051] A spray-drying process for preparing ultra-fine powders of
drugs is described, for example, in U.S. Pat. No. 6,051,256.
Freeze-drying procedures are well known in the art, and are
described, for example, in U.S. Pat. No. 4,608,764 and U.S. Pat.
No. 4,848,094. Spray-freeze-drying processes are described, for
example, in U.S. Pat. No. 5,208,998. Other spray-drying techniques
are described, in U.S. Pat. Nos. 6,253,463; 6,001,336; 5,260,306;
and PCT International Publication Nos. WO91/16882 and WO
96/09814.
[0052] Lyophilization techniques are well known to those skilled in
the art. Basically, lyophilization is a dehydration technique that
takes place while a product is in a frozen state and under a vacuum
(ice sublimation under a vacuum) and drying by gentle heating.
These conditions stabilize the product, and minimize oxidation and
other degradative processes. The conditions of freeze drying permit
running the process at low temperatures, therefore, thermally
labile products can be preserved. Steps in freeze drying include
pretreatment, freezing, primary drying and secondary drying.
Pretreatment includes any method of treating the product prior to
freezing. This may include concentrating the product, formulation
revision (i.e., addition of components to increase stability and/or
improve processing), decreasing a high vapor pressure solvent or
increasing the surface area. Methods of pretreatment include:
freeze concentration, solution phase concentration, and formulating
specifically to preserve product appearance or to provide
lyoprotection for reactive products, and are described, e.g., in
U.S. Pat. No. 6,199,297. "Standard" lyophilization conditions, are
described, e.g., in U.S. Pat. No. 5,031,336, and in "Freeze Drying
of Pharmaceuticals" (DeLuca, Patrick P., J. Vac. Sci. Technol.,
Vol. 14, No. 1, January/February 1977); and "The Lyophilization of
Pharmaceuticals: A Literature Review" (Williams, N. A., and G. P.
Polli, Journal of Parenteral Science and Technology, Vol. 38, No.
2, March/April 1984).
[0053] In certain aspects, the lyophilization cycle can be
partially performed above the glass transition temperature (Tg) of
the therapeutic agent formulation to induce a collapse of the mass
to form a dense cake containing residual water. In other
embodiments, the lyophilization cycle is carried out below the
glass transition temperature in order to avoid a collapse in order
to achieve a complete drying of the particles.
D. Moisture Content of Formulations
[0054] An additional key aspect of the formulations of the present
invention is that they have a low moisture content by virtue of
using the previously described non-aqueous solvents. This provides
for additional stability of both the formulation and the small
molecule drug. For instance, the stable formulations of the present
invention can have a moisture content that is less than 10%, 9%,
8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.1%, 0.05%, 0.025%,
0.01%, to 0% by weight or volume of the formulation. In some
instances, the formulation includes from about 0.01% to about 3%,
from about 0.01% to about 2%, from about 0.01% to about 1.5% or
from about 0.01% to about 1% by weight or volume of water in the
formulation.
E. Dosages
[0055] Any suitable dosage of drugs can be administered using the
formulations of the present invention. The dosage administered
will, of course, vary depending upon known factors, such as: the
pharmacodynamic characteristics of the particular drug, salt, or
combination thereof; the age, health, or weight of the subject; the
nature and extent of symptoms; the metabolic characteristics of the
therapeutic agent and patient, the kind of concurrent treatment;
the frequency of treatment; or the effect desired. Generally, the
drug is present in the formulation in an amount ranging from about
0.5 mg/mL to about 3000 mg/mL or up to the solubility limit of the
drug in the formulation. In some embodiments, the drug is present
in the formulation in an amount ranging from about 10 mg/mL to
about 50 mg/mL. In other embodiments, the drug is present in the
formulation in an amount ranging from about 20 mg/mL to about 50
mg/mL. In still other embodiments, the drug is present in said
formulation in an amount ranging from about 5 mg/mL to about 15
mg/mL. In yet other embodiments, the drug is present in the
formulation in an amount ranging from about 0.5 mg/mL to about 2
mg/mL. Again, it will be readily apparent to those of skill that
the drug dosage can be varied depending on the drug used and the
disease, disorder or condition to be treated, and the concentration
of the drug in the formulation will vary depending on the drug
solubility, dosage, and method of administration.
F. Additional Ingredients/Pharmaceutical Excipients
[0056] While the formulations of the present invention are
sufficient and useful with a small molecule drug and a
biocompatible non-aqueous solvent (see Example 1, Tables 1-2), the
formulation can include additional ingredients/pharmaceutical
excipients to further develop a formula to have a desired tactile
property, viscosity range, or to further protect the drug active.
For instance, the formulations can further include any one of, any
combination of, or all of an antioxidant (non-limiting examples of
which include ascorbic acid, cysteine, methionine,
monothioglycerol, sodium thiosulfate, sulfites, BHT, BHA, ascorbyl
palmitate, propyl gallate, or vitamin E or any combination
thereof); a chelating agent (non-limiting examples of which include
EDTA, EGTA, tartaric acid and salts thereof, glycerin, and citric
acid and salts thereof); and/or a preservative (non-limiting
examples of which include alkyl alcohols, benzyl alcohols, methyl
parabens, propyl parabens and mixtures thereof). Further, the
formulations of the present invention can also include a
non-aqueous protic solvent (non-limiting examples of which include
polyethylene glycol (PEG), propylene glycol (PG),
polyvinylpyrrolidone (PVP), methoxypropylene glycol (MPEG),
glycerol, glycofurol, and mixtures thereof).
G. Kits/Containers
[0057] Kits are also contemplated as being used in certain aspects
of the present invention. For instance, a formulation of the
present invention can be included within a kit. A kit can include a
container. In one aspect, for instance, the formulation can be
comprised within a container that is ready to parenterally
administer to a subject without having to reconstitute or dilute
the formulation. That is, the formulation to be administered can be
stored in the container and be readily used as needed. The
container can be a device. The device can be a syringe, a pen
injection device, an auto-injector device, a device that can pump
or administer the formulation (e.g., automatic or non-automatic
external pumps, implantable pumps, etc.) or a perfusion bag.
Suitable pen/auto-injector devices include, but are not limited to,
those pen/auto-injection devices manufactured by Becton-Dickenson,
Swedish Healthcare Limited (SHL Group), YpsoMed Ag, and the like.
Suitable pump devices include, but are not limited to, those pump
devices manufactured by Tandem Diabetes Care, Inc., Delsys
Pharmaceuticals and the like.
[0058] Alternatively, a kit of the present invention can include
multiple containers or multiple compartments within a container.
Each container or multiple compartments can be used to store, for
instance, the biocompatible non-aqueous solvent and the small
molecule drug separately. Then, as needed, the solvent and drug can
be mixed together and administered immediately or stored for a
later time, as needed.
EXAMPLES
[0059] The present invention will be described in greater detail by
way of specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the invention
in any manner. Those of skill in the art will readily recognize a
variety of noncritical parameters which can be changed or modified
to yield essentially the same results.
Example 1
Solubility and Stability of Diazepam in Biocompatible Non-Aqueous
Solvents
[0060] Diazepam, a small molecule anti-anxiety/anti-convulsant drug
(MW=284.7 g/mol; anhydrous, Sigma-Aldrich, St. Louis, Mo.) powder
was mixed with various biocompatible, non-aqueous solvents in 50 mg
increments until it no longer dissolved. The maximum solubility of
diazepam at this resolution was thus determined, and is reported in
Table 1, along with the corresponding injection volume of a 20-mg
dose at these concentrations.
TABLE-US-00001 TABLE 1 Solubility Injection Volume, .mu.l Solvent
(mg/ml) Solubility (20 mg) NMP 535 Freely Soluble 37.4 DMSO 125
Freely Soluble 160 70:30 100* Freely Soluble 200 DMSO:NMP Benzyl
benzoate 125 Freely Soluble 160 Triacetin 50 Soluble 400 PEG 300 50
Soluble 400 *Highest concentration tested. Based on diazepam
solubility in DMSO and NMP alone, this value is expected to be at
least 125 mg/ml.
[0061] Table 2 provides definitions for solubility used in Table 1
and in the following tables.
TABLE-US-00002 TABLE 2 Parts of Solvent Solubility Range Solubility
per 1 Part Solute (g/ml) (mg/ml) Very Soluble <1 >1 >1000
Freely Soluble 1-10 0.1-1.0 100-1000 Soluble 10-30 0.03-0.1 30-100
Sparingly Soluble 30-100 0.01-0.03 10-30 Slightly Soluble 100-1000
0.001-0.01 1-10 Very Slightly 1000-10000 0.0001-0.001 0.1-1 Soluble
Practically >10000 <0.0001 <0.1 Insoluble or Insoluble
[0062] Diazepam solutions were prepared at various concentrations
and evaluated for stability over one or six months. Solutions in
Table 3 were prepared by diluting solubility test samples and were
stored in glass vials at ambient conditions, and solutions in Table
4 were prepared using the following process and stored in syringes
in stability chambers: [0063] (1) Prepare any blended solvents
(e.g., 70:30 DMSO:NMP) in their indicated proportions (v/v) and
mix. [0064] (2) Weigh a mass of diazepam powder appropriate for
final concentration of 50 or 100 mg/mL. [0065] (3) Dissolve
diazepam powder in approximately 70% final volume solvent in glass
volumetric flask fitted with ground glass stopper. [0066] (a) Stir
or sonicate solution. [0067] (b) Requires less than 20 minutes
dissolution time. [0068] (4) Add solvent complement to bring to
final solution volume. [0069] (5) Stopper the flask and mix
end-over-end at least 10 times. [0070] (6) Verify drug content and
purity via RP-HPLC. All prepared solutions remained clear by visual
inspection and no crystals were observed by light microscopy under
100.times. magnification in the highest concentration solutions
presented in Table 3 after 10 days. Drug content and purity were
evaluated using a verified USP RP-HPLC method. The absence of
particulates was evaluated using visible light spectroscopy to
measure transmittance at 630 nm. These data are detailed in Tables
3 and 4.
TABLE-US-00003 [0070] TABLE 3 Solvent (Diazepam % Purity %
Transmittance Concentration, mg/ml) Two Weeks Three Weeks One Month
One Month NMP (200/100/50) 99.73/NA/NA 99.84/99.85/99.86
99.87/99.88/99.9 NA/100/99.8 DMSO (125/100/50) 99.81/NA/NA
99.76/99.79/99.80 99.8/99.83/99.85 99.5/NA/100 Benzyl Benzoate
99.89/NA/NA 99.88/99.90/99.85 99.91/99.91/99.86 100/99.8/100
(125/100/50) 70:30 DMSO:NMP NA 99.78 99.87 99.5 (50)
TABLE-US-00004 TABLE 4 25.degree. C./60% Relative Humidity
40.degree. C./75% Relative Humidity Actual Actual Diazepam Months
Diazepam % % Diazepam % Formulation Concentration of Concentration
Drug % Transmittance Concentration Drug % % Solution (mg/ml)
Stability (mg/ml) Content Purity (630 nm) (mg/ml) Content Purity
Transmittance DMSO 50 T = 0 51.5 103.0% 100.00% 99.8 51.5 103.0%
100.00% 99.8 One 48.9 97.8% 99.88% 99.8 50.8 101.6% 99.47% 100.0
Three 50.9 101.7% 100.00% 100.0 49.2 98.3% 100.00% 100.0 Six 48.2
96.3% 100.00% 100.0 48.9 97.8% 100.00% 100.0 100 T = 0 102.4 102.4%
100.00% 99.8 102.4 102.4% 100.00% 99.8 One 99.6 99.6% 99.86% 100.0
99.2 99.2% 99.63% 100.0 Three 99.7 99.7% 100.00% 99.8 98.7 98.7%
99.99% 99.8 Six 98.7 98.7% 100.00% 99.8 81.0 81.0% 100.00% 100.0
NMP 50 T = 0 51.1 102.1% 99.80% 100.0 51.1 102.1% 99.80% 100.0 One
50.4 100.8% 99.97% 100.2 50.9 101.8% 99.95% 100.0 Three 50.5 101.0%
99.97% 100.0 50.1 100.1% 99.94% 100.0 Six 50.4 100.8% 99.94% 100.0
101.6 101.6% 99.96% 100.0 100 T = 0 104.3 104.3% 100.00% 99.8 104.3
104.3% 100.00% 99.8 One 102.4 102.4% 99.73% 99.8 103.2 103.2%
99.42% 100.0 Three 103.1 103.1% 99.98% 99.8 104.0 104.0% 99.96%
99.8 Six 103.3 103.3% 99.98% 99.5 103.5 103.5% 99.95% 99.8 70 DMSO/
50 T = 0 52.1 104.2% 99.99% 100.0 52.1 104.2% 99.99% 100.0 30 NMP
One 51.1 102.1% 99.96% 100.5 50.1 100.3% 99.87% 100.0 Three 51.4
102.7% 99.99% 100.0 47.8 95.6% 99.99% 99.8 Six 51.0 102.0% 100.00%
99.5 49.2 98.3% 99.98% 99.8 100 T = 0 103.6 103.6% 99.99% 100.0
103.6 103.6% 99.99% 100.0 One 101.2 101.2% 99.83% 100.5 102.5
102.5% 99.84% 100.7 Three 102.3 102.3% 99.99% 99.8 102.3 102.3%
99.97% 99.8 Six 100.8 100.8% 100.00% 99.8 98.7 98.7% 99.97% 99.5
Benzyl 50 T = 0 50.4 100.7% 99.86% 99.5 50.4 100.7% 99.86% 99.5
Benzoate One 50.3 100.6% 99.99% 100.0 50.2 100.4% 99.97% 99.5 Three
50.8 101.6% 99.97% 100.0 50.5 100.9% 99.96% 100.0 Six 50.1 100.1%
99.97% 100.0 50.0 100.0% 99.96% 100.0 100 T = 0 101.8 101.8%
100.00% 99.3 101.8 101.8% 100.00% 99.3 One 100.0 100.0% 99.50%
100.0 100.9 100.9% 99.75% 99.5 Three 100.8 100.8% 99.98% 99.9 103.1
103.1% 99.97% 99.8 Six 91.2 91.2% 99.97% 99.1 105.5 105.5% 99.98%
99.1
[0071] The formulations in Table 4 were placed into syringes (e.g.,
Daikyo Crystal Zenith syringes). To fill syringes, 500 .mu.L of
formulation was placed into syringes fitted with needle caps. A
long (11/2-inch) 20-gauge needle) was placed along the inner wall
of the syringe barrel and the plunger was guided down into the
barrel until the plunger passed the tip of the needle. This allowed
air to escape without pushing the sample out of the syringe.
Release testing of filled syringes was conducted to determine drug
content (RP-HPLC), purity (RP-HPLC) and transmittance (at 630 nm)
of the released formulation from the syringe. With the exception of
two formulations, all release samples had between 100.1% and 105.2%
target drug content, with at least 99.97% purity and at least 99.3%
transmittance.
Example 2
[0072] (Pharmacokinetics of Diazepam Formulations)
[0073] A study was conducted to establish the pharmacokinetic (PK)
profile in rats of four concentrated subcutaneous (SC) preparations
of diazepam compared to a control formulation of rectally
administered diazepam gel (Diastat, the prevailing at-home
treatment for seizures)). Briefly, five jugular vein-cannulated
(JVC) female Sprague-Dawley rats were dosed either by SC injection
with 10 uL of liquid diazepam test article, or rectally with 200
.mu.L of the control preparation utilizing a positive displacement
pipet. Animals were fasted for 12 hours, and a small application of
rectal glycerin prior to Diastat dosing were utilized to minimize
defecation and expulsion of drug product in control animals. Whole
blood samples were collected at 0 (pre), 3, 6, 9, 12, 20, 30, 45
minutes; 1, 1.5, 2, 3, and 4 hours post drug administration in
conical tubes pre-loaded with potassium EDTA anti-coagulant. Plasma
diazepam was analyzed as described below. Results are presented in
FIG. 1. The preclinical study was performed at Southwest Bio-Labs
(Las Cruces, N. Mex.). The study design is summarized in Table
5.
TABLE-US-00005 TABLE 5 Group Rats per Test Article/ Dose Route of
Target Dose Sample Time No. Group Formulation Volume (.mu.l)
Administration (mg/rat) Points* 1 5 Diastat Rectal Gel.sup.a 200
Rectal 1 0 (pre), 3, (Control) 6, 9, 12, 2 5 XeriSol .TM. Diazepam
10 SC 1 20, 30, 45 DMSO minutes; 1, 3 5 XeriSol .TM. Diazepam 10 SC
1 1.5, 2, 3, DMSO:NMO 70:30 and 4 h 4 5 XeriSol .TM. Diazepam 10 SC
1 post-drug NMP admin. 5 5 XeriSol .TM. Diazepam 10 SC 1 Benzyl
Benzoate .sup.aDiastat rectal gel is a non-sterile diazepam gel
provided in a prefilled, unit-dose, rectal delivery system. Diastat
rectal gel contains 5 mg/mL diazepam, propylene glycol, ethyl
alcohol (10%), hydroxypropyl methylcellulose, sodium benzoate,
benzyl alcohol (1.5%), benzoic acid and water, pH between
6.5-7.2.
There were a few noteworthy deviations from the study plan. The
jugular vein cannulas presented some difficulty to study personnel
and did not maintain patency throughout the study. Some blood
collections were consequently delayed by a matter of minutes (each
actual collection time was recorded by study personnel). Problems
with the JVC caused animals in each of the XeriSol.TM. groups to
require blood sampling from the retro-orbital sinus at various time
points. One animal each in the Diastat and XeriSol.TM. DMSO groups
were removed from the study due to complete cannula failure (prior
to substituting retro-orbital bleeds). Actual collection times were
used to generate individual animal time-concentration curves from
which pharmacological parameters were derived.
[0074] Diazepam plasma concentrations were measured at ICON
Development Solutions, LLC (Whitesboro, N.Y.). ICON used an
LC/MS/MS method validated for assay of diazepam in rat plasma.
Samples were frozen at the preclinical study site and shipped to
ICON on dry ice. Average diazepam concentrations for all groups at
nominal intervals post-administration are shown in FIG. 1.
[0075] Pharmacokinetic parameters were calculated from each
individual animal and averaged by treatment group. Standard
non-compartmental methods were utilized to perform calculations for
C.sub.max (the maximum diazepam concentration), T.sub.max (the time
that C.sub.max was observed, relative to dose administration), and
AUC (the area under the diazepam concentration versus time curve
from time 0 to 240 minutes). Additionally, the parameter T.sub.1/2
max was calculated (the time at which one-half maximum
concentration was observed). This parameter is useful when
C.sub.max occurs within a broad peak or when levels around
C.sub.max are reached quickly and then sustained, as was observed
in some groups. T.sub.1/2 max was derived by performing a linear
regression on the initial absorption phase of the curves, and using
the equation T.sub.1/2
max=[(0.5.times.C.sub.max)-(y-intercept)]/slope. Analyses of the
pharmacokinetic parameters were performed using SAS statistical
software. Bioequivalence could not be determined due to incomplete
clearance of the XeriSol diazepam formulations at the end of the
study. Data are shown in Table 6.
TABLE-US-00006 TABLE 6 Group C.sub.max, ng/mL Area under the curve
T.sub.max, minutes T.sub.1/2 max, minutes Diastat 285.00 (44.10)
10380 (5233) 4.5 (1.7) 1.9 (0.4) NMP 378.34 (467.53) 31719 (16921)
8.0 (4.2) 3.6 (1.8) DMSO 89.28 (34.55) 13936 (2591) 129.8 (127.6)
5.1 (3.1) DMSO/NMP 92.90 (35.20) 14967 (5989) 100.2 (127.6) 3.0
(1.0) Benzyl Benzoate 22.06 (15.61) 4093 (3332) 204.0 (80.5)
N/A
[0076] These data suggest that among the XeriSol.TM. groups, the
order of effectiveness of the formulations is
NMP>NMP:DMSO>DMSO>benzyl benzoate. It is clear that of the
XeriSol.TM. formulations, NMP has the most favorable PK profile and
is most comparable to the Diastat control. While all the
XeriSol.TM. formulations, with the exception of benzyl benzoate,
have increased AUC over Diastat, three of the XeriSol.TM.
formulations fail to reach one third the C.sub.max of Diastat.
XeriSol.TM. NMP, on the other hand, exceeds the Diastat C.sub.max
by 33%. Diastat did have the shortest T.sub.max of all groups, but
the XeriSol.TM. formulations raised plasma diazepam in comparably
short times, again with the exception of benzyl benzoate. Whereas
T.sub.max is large for all but XeriSol.TM. NMP, T.sub.1/2 max
demonstrates that this is an artifact of sustained concentrations
of plasma diazepam near (or slightly above) a concentration that
was achieved early in the time course (T.sub.1/2 max was not
calculated for benzyl benzoate, as C.sub.max was reached in only
one animal; plasma diazepam continuously increased in the other
four animals).
[0077] The differing C.sub.max's between the XeriSol.TM.
formulations may be solubility-related, as the C.sub.max trend
follows that of diazepam solubility in the solvents. The time to
appear in the blood may be governed in part by the time required to
dissolve diazepam should a precipitation event occur upon
introduction to the aqueous subcutaneous environment--an event more
likely with a lower solubility limit in the vehicle. This
information could be useful for tailoring the PK profile through
solvent combinations.
[0078] Regarding the sustained elevation of plasma diazepam in
XeriSol.TM. groups relative to Diastat controls, differences in
blood flow might be causative. From a subcutaneous injection site,
diazepam presumably would enter the general circulation and have
more time to accumulate in the blood vs. draining quite directly
from the rectal blood supply to the liver for metabolism, as is
likely the case with Diastat. This phenomenon of sustained
concentrations would thus be more difficult to control. However, a
sustained blood diazepam, occurring in all XeriSol.TM. groups
throughout the duration of the study, while a measure against
bioequivalence with Diastat, could prove beneficial for not only
the treatment of an active seizure, but also for the prevention of
follow-on or cluster seizures. This benefit would be particularly
realized in the XeriSol.TM. NMP formulation, considered in
combination with its rapid absorption profile and high C.sub.max.
Such a PK profile could also indicate that XeriSol.TM. diazepam may
be able to attain therapeutic levels of diazepam using less drug
substance per dose than Diastat.
Example 3
Solubility of Lorazepam in Biocompatible Non-Aqueous Solvents
[0079] Lorazepam, a small molecule anti-anxiety/anti-convulsant
agent (MW=321.16 g/mol) was mixed with 1 gram of the following
biocompatible, non-aqueous solvent in approximately 10 milligram
increments until it no longer dissolved: benzyl benzoate, DMSO,
NMP, Triacetin, and PEG 300. Once 50 mg of drug had been added to
the solution (and the drug was still completely soluble in the
solvent), the increments of drug added in each step increased to
approximately 25 mg, and was maintained at approximately 25 mg
until the drug no longer dissolved completely in the solution. This
allowed the maximum solubility of lorazepam at this resolution to
be determined for each of the five biocompatible non-aqueous
solvents, as shown in Table 7.
TABLE-US-00007 TABLE 7 Solvent Solubility (mg/mL) Solubility Benzyl
Benzoate 10 Sparingly Soluble DMSO 100 Freely Soluble NMP 480
Freely Soluble Triacetin 20 Sparingly Soluble PEG 300 80
Soluble
Example 4
Solubility of Albuterol Sulfate in Biocompatible Non-Aqueous
Solvents
[0080] Albuterol sulfate, a small molecule
immuno-suppressive/anti-cancer agent (MW=288.35 g/mol) Was mixed
with the following biocompatible non-aqueous solvents (benzyl
benzoate, DMSO, NMP, 70:30 (v/v) DMSO:NMP, Triacetin, and PEG 300)
in amounts sufficient to prepare mixtures of increasing
concentration. Specifically, the concentrations examined were 0.1
mg/mL, 1.0 mg/mL, 5 mg/mL, 10 mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL,
and increasing increments of 50 mg/mL until the small molecule drug
no longer dissolved completely in the solvent. Accordingly, this
allowed the maximum solubility of albuterol sulfate at this
resolution to be determined for each of the six biocompatible
non-aqueous solvents, as shown in Table 8.
TABLE-US-00008 TABLE 8 Solvent Solubility (mg/mL) Solubility Benzyl
Benzoate <0.1 Practically insoluble DMSO 5 Slightly soluble NMP
<0.1 Practically insoluble 70:30 DMSO:NMP 5 Slightly soluble
Triacetin <0.1 Practically insoluble PEG 300 <0.1 Practically
insoluble
Example 5
Solubility of Atropine in Biocompatible Non-Aqueous Solvents
[0081] Atropine, a small molecule anti-cholinergic agent (MW=289.4
g/mol) was mixed with the following biocompatible non-aqueous
solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v) DMSO:NMP,
Triacetin, and PEG 300) in amounts sufficient to prepare mixtures
of increasing concentration. Specifically, the concentrations
examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10 mg/mL, 30 mg/mL, 50
mg/mL, 100 mg/mL, and increasing increments of 50 mg/mL until the
small molecule drug no longer dissolved completely in the solvent.
Accordingly, this allowed the maximum solubility of atropine at
this resolution to be determined for each of the six biocompatible
non-aqueous solvents, as shown in Table 9.
TABLE-US-00009 TABLE 9 Solvent Solubility (mg/mL) Solubility Benzyl
Benzoate 30 Soluble DMSO 500 Freely soluble NMP 750 Freely soluble
70:30 DMSO:NMP 650 Freely soluble Triacetin 5 Slightly soluble PEG
300 30 Soluble
Example 6
Solubility of Cromolyn Sodium in Biocompatible Non-Aqueous
Solvents
[0082] Cromolyn sodium, a small molecule mast cell stabilizer
(MW=512.3 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of cromolyn sodium at this resolution to be determined
for each of the six biocompatible non-aqueous solvents, as shown in
Table 10.
TABLE-US-00010 TABLE 10 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate 0.1 Very slightly soluble DMSO 50 Soluble NMP 0.1
Very slightly soluble 70:30 DMSO:NMP 5 Slightly soluble Triacetin
0.1 Very slightly soluble PEG 300 50 Soluble
Example 7
Solubility of Lidocaine in Biocompatible Non-Aqueous Solvents
[0083] Lidocaine, a small molecule (MW=234.34 g/mol) was mixed with
the following biocompatible non-aqueous solvents (benzyl benzoate,
DMSO, NMP, 70:30 (v/v) DMSO:NMP, Triacetin, and PEG 300) in amounts
sufficient to prepare mixtures of increasing concentration.
Specifically, the concentrations examined were 0.1 mg/mL, 1.0
mg/mL, 5 mg/mL, 10 mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and
increasing increments of 50 mg/mL until the small molecule drug no
longer dissolved completely in the solvent. Accordingly, this
allowed the maximum solubility of lidocaine at this resolution to
be determined for each of the six biocompatible non-aqueous
solvents, as shown in Table 11.
TABLE-US-00011 TABLE 11 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate 900 Freely Soluble DMSO 2000 Very soluble NMP 1750
Very soluble 70:30 DMSO:NMP 1750 Very soluble Triacetin 400 Freely
soluble PEG 300 200 Freely soluble
Example 8
Solubility of Rifampicin in Biocompatible Non-Aqueous Solvents
[0084] Rifampicin, a small molecule anti-tubercular agent
(MW=822.94 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of rifampicin at this resolution to be determined for
each of the six biocompatible non-aqueous solvents, as shown in
Table 12.
TABLE-US-00012 TABLE 12 Solvent Solubility (mg/mL) Soluble Benzyl
Benzoate 50 Soluble DMSO 150 Freely soluble NMP 400 Freely soluble
70:30 DMSO:NMP 150 Freely soluble Triacetin 5 Slightly soluble PEG
300 5 Slightly soluble
Example 9
Solubility of Epinephrine Bitartrate in Biocompatible Non-Aqueous
Solvents
[0085] Epinephrine bitartrate, a small molecule sympathomimetic
(MW=333.3 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of epinephrine bitartrate at this resolution to be
determined for each of the six biocompatible non-aqueous solvents,
as shown in Table 13.
TABLE-US-00013 TABLE 13 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate <0.1 Practically insoluble DMSO 700 Freely
soluble NMP 400 Freely soluble 70:30 DMSO:NMP 500 Freely soluble
Triacetin <0.1 Practically insoluble PEG 300 0.1 Very slightly
soluble
Example 10
Solubility of Acetylsalicylic Acid in Biocompatible Non-Aqueous
Solvents
[0086] Acetylsalicylic acid, a small molecule analgesic agent
(MW=180.16 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of acetylsalicylic acid at this resolution to be
determined for each of the six biocompatible non-aqueous solvents,
as shown in Table 14.
TABLE-US-00014 TABLE 14 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate 30 Soluble DMSO 2000 Very soluble NMP 1200 Very
soluble 70:30 DMSO:NMP 1450 Very soluble Triacetin 5 Slightly
soluble PEG 300 5 Slightly soluble
Example 11
Solubility of Beclomethasone Dipropionate in Biocompatible
Non-Aqueous Solvents
[0087] Beclomethasone dipropionate, a small molecule corticosteroid
(MW=521.04 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of beclomethasone dipropionate at this resolution to be
determined for each of the six biocompatible non-aqueous solvents,
as shown in Table 15.
TABLE-US-00015 TABLE 15 Solvent Solubility (mg/mL) Soluble Benzyl
Benzoate 50 Soluble DMSO 1700 Very soluble NMP 1800 Very soluble
70:30 DMSO:NMP 1700 Very soluble Triacetin 5 Slightly soluble PEG
300 30 Soluble
Example 12
Solubility of Sumatriptan Succinate in Biocompatible Non-Aqueous
Solvents
[0088] Sumatriptan succinate, a small molecule anti-migraine drug
(MW=413.49 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of sumatriptan succinate at this resolution to be
determined for each of the six biocompatible non-aqueous solvents,
as shown in Table 16.
TABLE-US-00016 TABLE 16 Solvent Solubility (mg/mL) Soluble Benzyl
Benzoate <0.1 Practically insoluble DMSO 350 Freely soluble NMP
100 Freely soluble 70:30 DMSO:NMP 300 Freely soluble Triacetin
<0.1 Practically insoluble PEG 300 0.1 Very slightly soluble
Example 13
Solubility of Diphenhydramine Hydrochloride in Biocompatible
Non-Aqueous Solvents
[0089] Diphenhydramine hydrochloride, a small molecule
anti-histamine drug (MW=291.82 g/mol) was mixed with the following
biocompatible non-aqueous solvents (benzyl benzoate, DMSO, NMP,
70:30 (v/v) DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient
to prepare mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent. Accordingly, this allowed the maximum
solubility of diphenhydramine hydrochloride at this resolution to
be determined for each of the six biocompatible non-aqueous
solvents, as shown in Table 17.
TABLE-US-00017 TABLE 17 Solvent Solubility (mg/mL) Soluble Benzyl
Benzoate 0.1 Very slightly soluble DMSO 300 Freely soluble NMP 100
Freely soluble 70:30 DMSO:NMP 150 Freely soluble Triacetin 0.1 Very
slightly soluble PEG 300 50 Soluble
Example 14
Solubility of Fluconazole in Biocompatible Non-Aqueous Solvents
[0090] Fluconazole, a small molecule anti-fungal drug (MW=306.27
g/mol) was mixed with the following biocompatible non-aqueous
solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v) DMSO:NMP,
Triacetin, and PEG 300) in amounts sufficient to prepare mixtures
of increasing concentration. Specifically, the concentrations
examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10 mg/mL, 30 mg/mL, 50
mg/mL, 100 mg/mL, and increasing increments of 50 mg/mL until the
small molecule drug no longer dissolved completely in the solvent.
Accordingly, this allowed the maximum solubility of fluconazole at
this resolution to be determined for each of the six biocompatible
non-aqueous solvents, as shown in Table 18.
TABLE-US-00018 TABLE 18 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate 5 Slightly soluble DMSO 900 Freely soluble NMP 800
Freely soluble 70:30 DMSO:NMP 850 Freely soluble Triacetin 5
Slightly soluble PEG 300 50 Soluble
Example 15
Solubility of Tobramycin in Biocompatible Non-Aqueous Solvents
[0091] Tobramycin, a small molecule aminoglycoside antibiotic
(MW=467.51 g/mol) was mixed with the following biocompatible
non-aqueous solvents (benzyl benzoate, DMSO, NMP, 70:30 (v/v)
DMSO:NMP, Triacetin, and PEG 300) in amounts sufficient to prepare
mixtures of increasing concentration. Specifically, the
concentrations examined were 0.1 mg/mL, 1.0 mg/mL, 5 mg/mL, 10
mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL, and increasing increments of
50 mg/mL until the small molecule drug no longer dissolved
completely in the solvent completely in the solvent. Accordingly,
this allowed the maximum solubility of tobramycin at this
resolution to be determined for each of the six biocompatible
non-aqueous solvents, as shown in Table 19.
TABLE-US-00019 TABLE 19 Solvent Solubility (mg/mL) Solubility
Benzyl Benzoate <0.1 Practically insoluble DMSO <0.1
Practically insoluble NMP <0.1 Practically insoluble 70:30
DMSO:NMP <0.1 Practically insoluble Triacetin 0.1 Very slightly
soluble PEG 300 0.1 Very slightly soluble
Example 16
Solubility of Cyclophosphamide Monohydrate in Biocompatible
Non-Aqueous Solvents
[0092] Cyclophosphamide monohydrate, a small molecule
immuno-suppressive/anti-cancer agent (MW=279.10 g/mol) was mixed
with the following biocompatible non-aqueous solvents (benzyl
benzoate, DMSO, NMP, 70:30 (v/v) DMSO:NMP, Triacetin, and PEG 300)
in amounts sufficient to prepare mixtures of increasing
concentration. Specifically, the concentrations examined were 0.1
mg/mL, 1.0 mg/mL, 5 mg/mL, 10 mg/mL, 30 mg/mL, 50 mg/mL, 100 mg/mL,
and increasing increments of 50 mg/mL until the small molecule drug
no longer dissolved completely in the solvent. Accordingly, this
allowed the maximum solubility of cyclophosphamide monohydrate at
this resolution to be determined for each of the six biocompatible
non-aqueous solvents, as shown in Table 20.
TABLE-US-00020 TABLE 20 Solvent Solubility (mg/mL) Soluble Benzyl
Benzoate 100 Freely soluble DMSO 2800 Very soluble NMP 2100 Very
soluble 70:30 DMSO:NMP 2700 Very soluble Triacetin 150 Freely
soluble PEG 300 100 Freely soluble
[0093] All of the ingredients, compositions, or methods disclosed
and claimed in this specification can be made and executed without
undue experimentation in light of the present disclosure. While the
ingredients, compositions, or methods of this invention have been
described in terms of particular embodiments, it will be apparent
to those of skill in the art that variations may be applied to the
active ingredients, compositions, or methods and in the steps or in
the sequence of steps of the method described herein without
departing from the concept, spirit and scope of the invention.
* * * * *